Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of bevacizumab plus chemotherapy in progressive well-differentiated advanced or metastatic digestive neuroendocrine tumors
2006-005144-84Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Gastroenteropancreatic Carcinoid Tumor and gastrointestinal carcinoid tumor comparing Bevacizumab + capecitabine + streptozocin with Bevacizumab + fluorouracil + streptozocin (2 arms). Primary endpoint: Progression-free survival. Started Nov 2006; status: completed.
02
Drugs
bevacizumabcapecitabinestreptozocinfluorouracil
03
Conditions
Gastroenteropancreatic Carcinoid Tumorgastrointestinal carcinoid tumor
Beyond the preview
Go deeper on 2006-005144-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005144-84.